Product Description
STRO-002, a folate receptor alpha (FolR_)-targeting ADC, is currently being investigated in a Phase 1 clinical trial for patients with ovarian and endometrial cancers and was granted Fast Track designation by the FDA for ovarian cancer. (Sourced from: https://www.sutrobio.com/sutro-biopharma-announces-interim-data-from-dose-expansion-cohort-of-stro-002-phase-1-study-for-patients-with-advanced-ovarian-cancer/)
Mechanisms of Action: FR1 Antagonist
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: Fast Track - Ovarian Cancer *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sutro Biopharma, Inc.
Company Location: SOUTH SAN FRANCISCO CA 94080
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Belgium, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Hungary, Ireland, Israel, Italy, Korea, Netherlands, New Zealand, Singapore, Spain, United States
Active Clinical Trial Count: 8
Highest Development Phases
Phase 3: Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cancer
Phase 2: Acute Myeloid Leukemia|Non-Small-Cell Lung Cancer
Phase 1: Adenocarcinoma|Endometrial Cancer|Endometrioid Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| GLIS2 AML | P2 |
Recruiting |
Acute Myeloid Leukemia |
2028-12-01 |
|
| REFRaME-O1 | P3 |
Recruiting |
Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer |
2027-08-01 |
|
| TSL-B2276-1-01 | P2 |
Recruiting |
Ovarian Cancer |
2026-12-30 |
57% |
| REFRaME-L1 | P2 |
Recruiting |
Non-Small-Cell Lung Cancer |
2026-10-01 |